<DOC>
	<DOCNO>NCT02041221</DOCNO>
	<brief_summary>Sun Pharma Advanced Research company Limited develop dry powder inhaler compound SPARC1316 oral inhalation . This clinical study Phase I/IIa study investigate safety , tolerability , pharmacokinetics pharmacodynamics single multiple ascend dos S0597 administer oral inhalation healthy volunteer asthma patient .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics SPARC1316</brief_title>
	<detailed_description />
	<criteria>Subjects willing provide inform consent Male female subject age 18 65 year inclusive Body mass index ( BMI ) 18.0 30.0 kg/m2 inclusive Nonsmokers exsmokers Subjects supine systolic blood pressure ≥160 mmHg and/or supine diastolic blood pressure ≥100 mmHg Subjects significant infection know inflammatory process screen admission . Subjects unlikely cooperate requirement study . Positive serology infectious disease ( hepatitisB C , HIV ) screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>pharmacokinetics , pharmacodynamics , asthma</keyword>
</DOC>